SCHEMBL17494192

SCHEMBL17494192

COC(=O)CC(NC(=O)[C@@H](NC(=O)c1ccc2ccccc2n1)C(C)C)C(=O)COc1c(F)cccc1F

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 19/20 0.54
CASP6 P55212 18/20 0.54
CASP8 Q14790 18/20 0.54
CASP7 P55210 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17494193 1.00 CASP3 (0.54) CASP3CASP6CASP8CASP7
SCHEMBL17494191 1.00 CASP3 (0.54) CASP3CASP6CASP8CASP7
SCHEMBL11896297 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL11896298 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL11896299 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL11911364 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL2878062 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL2878064 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL20870231 0.94 CASP3 (0.49) CASP3CASP6CASP8
SCHEMBL15947165 0.92 CASP3 (0.63) CASP3CASP6CASP8CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210007348-A1 STABILIZATION OF WHOLE BLOOD SAMPLES THE GENERAL HOSPITAL CORPORATION 2021-01-14 US claimed
EP-3698628-A1 STABILIZATION OF WHOLE BLOOD SAMPLES The General Hospital Corporation (US) 2020-08-26 EP claimed
EP-3177924-A1 STABILIZATION OF WHOLE BLOOD SAMPLES The General Hospital Corporation (US) 2017-06-14 EP claimed
WO-2016022433-A1 STABILIZATION OF WHOLE BLOOD SAMPLES THE GENERAL HOSPITAL CORPORATION (US) 2016-02-11 WO claimed
US-11612163-B2 Stabilization of whole blood samples THE GENERAL HOSPITAL CORPORATION (US) 2023-03-28 US disclosed
US-20220251627-A1 COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF ZYMO RESEARCH CORPORATION (US) 2022-08-11 US disclosed
WO-2022123062-A1 BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2022-06-16 WO disclosed
EP-3989722-A1 COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF Zymo Research Corporation (US) 2022-05-04 EP disclosed
US-20210007348-A1 STABILIZATION OF WHOLE BLOOD SAMPLES THE GENERAL HOSPITAL CORPORATION 2021-01-14 US disclosed
WO-2020264313-A1 COMPOSITIONS FOR THE STABILIZATION OF CELL-FREE NUCLEIC ACIDS AND METHODS THEREOF ZYMO RESEARCH CORPORATION (US) 2020-12-30 WO disclosed
EP-3698628-A1 STABILIZATION OF WHOLE BLOOD SAMPLES The General Hospital Corporation (US) 2020-08-26 EP disclosed
US-10750739-B2 Stabilization of whole blood samples THE GENERAL HOSPITAL CORPORATION (US) 2020-08-25 US disclosed
US-20170223949-A1 STABILIZATION OF WHOLE BLOOD SAMPLES THE GENERAL HOSPITAL CORPORATION 2017-08-10 US disclosed
EP-3177924-A1 STABILIZATION OF WHOLE BLOOD SAMPLES The General Hospital Corporation (US) 2017-06-14 EP disclosed
WO-2016022433-A1 STABILIZATION OF WHOLE BLOOD SAMPLES THE GENERAL HOSPITAL CORPORATION (US) 2016-02-11 WO disclosed